Beyond The Patent Cliff: Pharma's New Growth Engines
AbbVie raised its profit outlook, proving it can thrive after its blockbuster Humira faced competition. This creates an investment opportunity in resilient pharmaceutical companies that are successfully launching new drugs to replace older ones.
Your Basket's Financial Footprint
Market capitalisation breakdown for the pharmaceutical-focused basket 'Beyond The Patent Cliff: Pharma's New Growth Engines'.
- Large-cap dominance generally implies lower volatility and closer tracking to broad market performance, indicating more stable returns.
- Best used as a core holding for diversified portfolios, not as a speculative or short-term trade.
- Generally expect steady long-term value rather than rapid, short-term appreciation.
ABBV: $408.76B
PFE: $141.29B
VRTX: $109.29B
- Other
About This Group of Stocks
Our Expert Thinking
AbbVie's successful transition from Humira to new blockbusters like Skyrizi and Rinvoq proves that pharmaceutical companies can thrive beyond patent cliffs. This creates opportunities in drugmakers with strong research pipelines that can replace aging products with innovative treatments, positioning them for long-term growth in the healthcare sector.
What You Need to Know
Patent cliffs occur when blockbuster drugs lose exclusivity, often causing significant revenue declines. However, companies with robust research and development capabilities can navigate this challenge by launching next-generation therapies. This group focuses on resilient pharmaceutical firms with proven or potential ability to manage these critical transitions.
Why These Stocks
These pharmaceutical companies were handpicked by professional analysts for their promising drug pipelines and demonstrated ability to replace revenues from expiring patents. Each firm represents the potential to unlock substantial growth as new revenue streams mature, making them attractive for long-term healthcare sector investment.
Why You'll Want to Watch These Stocks
Pipeline Power
These companies are proving that smart research and development can turn potential patent disasters into growth opportunities. When new drugs succeed, the rewards can be massive.
Innovation Advantage
AbbVie's success story shows that pharmaceutical companies with strong pipelines can not only survive patent cliffs but actually thrive. This blueprint could work for others in the group.
Expert-Backed Selection
Professional analysts handpicked these companies for their ability to navigate one of pharma's biggest challenges. Each represents potential for substantial long-term growth in healthcare.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Industrial Automation Stocks | UAE Manufacturing Hub
The United Arab Emirates is expanding its manufacturing and industrial sectors as a core part of its economic diversification strategy. This basket offers exposure to US and EU-listed companies in industrial automation, robotics, and specialty chemicals that supply this growth.
UAE Sustainable Urban Development | Smart City Stocks
The UAE's strategic push towards economic diversification and world-class cities creates significant opportunities in urban infrastructure. This basket offers exposure to US and EU-listed global firms that supply the technology and materials for these ambitious projects.
UAE Manufacturing Surge | Picks and Shovels Approach
The United Arab Emirates is rapidly expanding its non-oil economy, driving significant demand for industrial infrastructure and materials. This basket offers exposure to the global US/EU-listed companies supplying the essential equipment, chemicals, and engineering services for this growth.